7.315USD+1.18%Mkt Cap: 194.78M USDP/E: —Last update: 2026-05-26
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARC…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap194.78M USD
Enterprise Value111.77M USD
Revenue (TTM)45.07M USD
Gross Profit45.07M USD
Net Income (TTM)-45.72M USD
Revenue/Share2.705 USD
Last Price7.315 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees68
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS74019P1084
Valuation
P/E (Trailing)—
P/E (Forward)-3.73
PEG—
EV/EBITDA-2.96
EV/Revenue2.48
P/S4.09
P/B1.87
EPS (TTM)-2.17
EPS (Forward)-1.92
52W Range
3.53072% of range8.820
52W High8.820 USD
52W Low3.530 USD
Profitability
Gross Margin100.00%
Oper. Margin-83.73%
EBITDA Margin-83.73%
Profit Margin-133.45%
ROE-49.57%
ROA-29.61%
Growth
Revenue Growth37272.40%
Earnings Growth—
Cash Flow & Leverage
Operating CF-65.84M USD
CapEx (TTM)700.00K USD
FCF Margin-48.07%
FCF Yield-11.12%
Net Debt-72.72M USD
Net Debt/EBITDA1.93
Balance Sheet
Debt/Equity0.31
Current Ratio14.02
Quick Ratio13.56
Book Value/Sh3.830 USD
Cash/Share3.922 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:30
Split DateFeb 14, 2024
Analyst Consensus
Rating1.0 (Strong Buy)
Target (Mean)32.00 USD
Target Range19.00 USD – 60.00 USD
# Analysts4
Ownership
Shares Out.25.80M
Float20.11M
Insiders6.03%
Institutions65.58%
Short Interest
Short Ratio6.4d
Short % Float5.63%
Short % Out.5.48%
Shares Short1.41M
Short (prev mo.)1.17M
Technical
SMA 506.934 (+5.5%)
SMA 2005.466 (+33.8%)
Beta1.31
S&P 52W Chg28.31%
Avg Vol (30d)216.70K
Avg Vol (10d)234.75K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—